单磷酸脂A佐剂超短疗程花粉变应原制剂皮下注射的安全性：一项意大利前瞻性调查

Safety of ultrashort-term sit with pollen allergoids adjuvanted by monophosphoryl lipid A: a prospective Italian survey.

作者信息

Crivellaro M, Senna G E, Pappacoda A, Vanzelli R, Spacal B, Marchi G, Recchia G, Makatsori M

机构信息

Department of Environmental Medicine, Allergology Service, University of Padova, Italy.

出版信息

Eur Ann Allergy Clin Immunol. 2011 Mar;43(2):58-60.

PMID:21608374

Abstract

A 3-year prospective post marketing survey on the safety of the recently developed ultrashort pre-seasonal subcutaneous immunotherapy (uSCIT-MPL4) with pollen allergoids adjuvanted with monophosphoryl lipid A was performed. A total of 510 patients received uSCIT-MPL4, 61% for grass, 35.7% for birch, 13.2% for parietaria and 3% for other pollens (ragweed, mugwort, and olive). A total of 3308 injections were given and the mean duration of uSCIT-MPL-4 was 2.3 years. Overall, only 7 slight systemic reactions (SR) were observed in 510 patients (1.37%) and 2.11/1000 injections suggesting that this treatment is even safer than traditional depot injection SIT.

摘要

对最近开发的、用单磷酰脂质A佐剂的花粉变应原进行超短季节性皮下免疫疗法（uSCIT-MPL4）的安全性进行了为期3年的上市后前瞻性调查。共有510名患者接受了uSCIT-MPL4治疗，其中61%针对禾本科花粉，35.7%针对桦树花粉，13.2%针对墙草花粉，3%针对其他花粉（豚草、艾蒿和橄榄花粉）。总共进行了3308次注射，uSCIT-MPL-4的平均疗程为2.3年。总体而言，在510名患者中仅观察到7例轻微全身反应（SR）（1.37%），每1000次注射中有2.11例，这表明该治疗甚至比传统的长效注射免疫疗法更安全。